Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

343 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The first report of the Italian Migraine Registry (I-GRAINE).
Barbanti P, Egeo G, Aurilia C, Fiorentini G, Proietti S, Tomino C, Bonassi S; Italian Migraine Registry Study Group. Barbanti P, et al. Among authors: fiorentini g. Neurol Sci. 2022 Sep;43(9):5725-5728. doi: 10.1007/s10072-022-06214-5. Epub 2022 Jul 8. Neurol Sci. 2022. PMID: 35802219
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients.
Barbanti P, Egeo G, Aurilia C, Altamura C, d'Onofrio F, Finocchi C, Albanese M, Aguggia M, Rao R, Zucco M, Frediani F, Filippi M, Messina R, Cevoli S, Carnevale A, Fiorentini G, Messina S, Bono F, Torelli P, Proietti S, Bonassi S, Vernieri F; Italian Migraine Registry study group. Barbanti P, et al. Among authors: fiorentini g. J Headache Pain. 2022 Nov 1;23(1):138. doi: 10.1186/s10194-022-01498-6. J Headache Pain. 2022. PMID: 36316648 Free PMC article.
Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study.
Barbanti P, Egeo G, Aurilia C, Torelli P, Finocchi C, d'Onofrio F, d'Onofrio L, Rao R, Messina S, Di Clemente L, Ranieri A, Autunno M, Sette G, Colombo B, Carnevale A, Aguggia M, Tasillo M, Zoroddu F, Frediani F, Filippi M, Tomino C, Proietti S, Bonassi S; FRIEND-Study Group. Barbanti P, et al. J Headache Pain. 2023 Mar 23;24(1):30. doi: 10.1186/s10194-023-01561-w. J Headache Pain. 2023. PMID: 36949388 Free PMC article.
Very-low-calorie ketogenic diet vs hypocaloric balanced diet in the prevention of high-frequency episodic migraine: the EMIKETO randomized, controlled trial.
Caprio M, Moriconi E, Camajani E, Feraco A, Marzolla V, Vitiello L, Proietti S, Armani A, Gorini S, Mammi C, Egeo G, Aurilia C, Fiorentini G, Tomino C, Barbanti P. Caprio M, et al. Among authors: fiorentini g. J Transl Med. 2023 Oct 4;21(1):692. doi: 10.1186/s12967-023-04561-1. J Transl Med. 2023. PMID: 37794395 Free PMC article. Clinical Trial.
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study.
Barbanti P, Aurilia C, Egeo G, Proietti S, D'Onofrio F, Torelli P, Aguggia M, Bertuzzo D, Finocchi C, Trimboli M, Cevoli S, Fiorentini G, Orlando B, Zucco M, Di Clemente L, Cetta I, Colombo B, di Poggio MLB, Favoni V, Grazzi L, Salerno A, Carnevale A, Robotti M, Frediani F, Altamura C, Filippi M, Vernieri F, Bonassi S; ERT; for the Italian Migraine Registry study group. Barbanti P, et al. Among authors: fiorentini g. J Neurol. 2024 May;271(5):2434-2443. doi: 10.1007/s00415-023-12103-4. Epub 2024 Jan 17. J Neurol. 2024. PMID: 38231271 Free PMC article.
Impact of multiple treatment cycles with anti-CGRP monoclonal antibodies on migraine course: focus on discontinuation periods. Insights from the multicenter, prospective, I-GRAINE study.
Barbanti P, Aurilia C, Egeo G, Proietti S, Torelli P, d'Onofrio F, Carnevale A, Tavani S, Orlando B, Fiorentini G, Colombo B, Filippi M, Bonassi S, Cevoli S; Italian Migraine Registry (I-GRAINE) study group. Barbanti P, et al. Among authors: fiorentini g. J Neurol. 2024 May;271(5):2605-2614. doi: 10.1007/s00415-024-12192-9. Epub 2024 Feb 12. J Neurol. 2024. PMID: 38342785 Free PMC article.
Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study.
Barbanti P, Egeo G, Proietti S, d'Onofrio F, Aurilia C, Finocchi C, Di Clemente L, Zucco M, Doretti A, Messina S, Autunno M, Ranieri A, Carnevale A, Colombo B, Filippi M, Tasillo M, Rinalduzzi S, Querzani P, Sette G, Forino L, Zoroddu F, Robotti M, Valenza A, Camarda C, Borrello L, Aguggia M, Viticchi G, Tomino C, Fiorentini G, Orlando B, Bonassi S, Torelli P; Italian Migraine Registry study group. Barbanti P, et al. Among authors: fiorentini g. Neurol Ther. 2024 Jun;13(3):611-624. doi: 10.1007/s40120-024-00591-z. Epub 2024 Mar 7. Neurol Ther. 2024. PMID: 38451463 Free PMC article.
Correction to: Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study.
Barbanti P, Aurilia C, Egeo G, Proietti S, D'Onofrio F, Torelli P, Aguggia M, Bertuzzo D, Finocchi C, Trimboli M, Cevoli S, Fiorentini G, Orlando B, Zucco M, Di Clemente L, Cetta I, Colombo B, di Poggio MLB, Favoni V, Grazzi L, Salerno A, Carnevale A, Robotti M, Frediani F, Altamura C, Filippi M, Vernieri F, Bonassi S; Italian Migraine Registry study group. Barbanti P, et al. Among authors: fiorentini g. J Neurol. 2024 May;271(5):2444-2445. doi: 10.1007/s00415-024-12287-3. J Neurol. 2024. PMID: 38564057 Free PMC article. No abstract available.
Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE-The First Italian Multicenter, Prospective, Real-Life Study.
Barbanti P, Orlando B, Egeo G, d'Onofrio F, Doretti A, Messina S, Autunno M, Messina R, Filippi M, Fiorentini G, Rotondi C, Bonassi S, Aurilia C. Barbanti P, et al. Among authors: fiorentini g. Brain Sci. 2024 Jun 30;14(7):672. doi: 10.3390/brainsci14070672. Brain Sci. 2024. PMID: 39061413 Free PMC article.
343 results